This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ramírez, J. C.
Right arrow Articles by Esteban, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ramírez, J. C.
Right arrow Articles by Esteban, M.

 Previous Article  |  Next Article 

Journal of Virology, January 2000, p. 923-933, Vol. 74, No. 2
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Biology of Attenuated Modified Vaccinia Virus Ankara Recombinant Vector in Mice: Virus Fate and Activation of B- and T-Cell Immune Responses in Comparison with the Western Reserve Strain and Advantages as a Vaccine

Juan C. Ramírez, M. Magdalena Gherardi, and Mariano Esteban*

Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, CSIC, Campus Universidad Autonoma, 28049 Madrid, Spain

Received 10 August 1999/Accepted 7 October 1999

The modified vaccinia virus Ankara (MVA) strain is a candidate vector for vaccination against pathogens and tumors, due to safety concerns and the proven ability of recombinants based on this vector to trigger protection against pathogens in animals. In this study we addressed the fate of the MVA vector in BALB/c mice after intraperitoneal inoculation in comparison with that of the replication-competent Western Reserve (WR) strain by measuring levels of expression of the reporter luciferase gene, the capability to infect target tissues from the site of inoculation, and the length of time of virus persistence. We evaluated the extent of humoral and cellular immune responses induced against the virus antigens and a recombinant product (beta -galactosidase). We found that MVA infects the same target tissues as the WR strain; surprisingly, within 6 h postinoculation the levels of expression of antigens were higher in tissues from MVA-infected mice than in tissues from mice infected with wild-type virus but at later times postinoculation were 2 to 4 log units higher in tissues from WR-infected mice. In spite of this, antibodies and cellular immune responses to viral vector antigens were considerably lower in MVA-inoculated mice than in WR virus-inoculated mice. In contrast, the cellular immune response to a foreign antigen expressed from MVA was similar to and even higher than that triggered by the recombinant WR virus. MVA elicited a Th1 type of immune response, and the main proinflammatory cytokines induced were interleukin-6 and tumor necrosis factor alpha. Our findings have defined the biological characteristics of MVA infection in tissues and the immune parameters activated in the course of virus infection. These results are of significance with respect to optimal use of MVA as a vaccine.

* Corresponding author. Mailing address: Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, CSIC, Campus Universidad Autonoma, 28049 Madrid, Spain. Phone: 34-91 5854503. Fax: 34-91 5854506. E-mail: mesteban{at}cnb.uam.es.

Journal of Virology, January 2000, p. 923-933, Vol. 74, No. 2
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Berhanu, A., Wilson, R. L., Kirkwood-Watts, D. L., King, D. S., Warren, T. K., Lund, S. A., Brown, L. L., Krupkin, A. K., VanderMay, E., Weimers, W., Honeychurch, K. M., Grosenbach, D. W., Jones, K. F., Hruby, D. E. (2008). Vaccination of BALB/c Mice with Escherichia coli-Expressed Vaccinia Virus Proteins A27L, B5R, and D8L Protects Mice from Lethal Vaccinia Virus Challenge. J. Virol. 82: 3517-3529 [Abstract] [Full Text]  
  • Bielinska, A. U., Chepurnov, A. A., Landers, J. J., Janczak, K. W., Chepurnova, T. S., Luker, G. D., Baker, J. R. Jr. (2008). A Novel, Killed-Virus Nasal Vaccinia Virus Vaccine. CVI 15: 348-358 [Abstract] [Full Text]  
  • Domingo-Gil, E., Perez-Jimenez, E., Ventoso, I., Najera, J. L., Esteban, M. (2008). Expression of the E3L Gene of Vaccinia Virus in Transgenic Mice Decreases Host Resistance to Vaccinia Virus and Leishmania major Infections. J. Virol. 82: 254-267 [Abstract] [Full Text]  
  • Gomez, C. E., Najera, J. L., Domingo-Gil, E., Ochoa-Callejero, L., Gonzalez-Aseguinolaza, G., Esteban, M. (2007). Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice. J. Gen. Virol. 88: 2473-2478 [Abstract] [Full Text]  
  • Stober, C. B., Lange, U. G., Roberts, M. T. M., Alcami, A., Blackwell, J. M. (2007). Heterologous Priming-Boosting with DNA and Modified Vaccinia Virus Ankara Expressing Tryparedoxin Peroxidase Promotes Long-Term Memory against Leishmania major in Susceptible BALB/c Mice. Infect. Immun. 75: 852-860 [Abstract] [Full Text]  
  • Chahroudi, A., Garber, D. A., Reeves, P., Liu, L., Kalman, D., Feinberg, M. B. (2006). Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus ankara and vaccinia virus.. J. Virol. 80: 8469-8481 [Abstract] [Full Text]  
  • Cottingham, M. G., van Maurik, A., Zago, M., Newton, A. T., Anderson, R. J., Howard, M. K., Schneider, J., Skinner, M. A. (2006). Different Levels of Immunogenicity of Two Strains of Fowlpox Virus as Recombinant Vaccine Vectors Eliciting T-Cell Responses in Heterologous Prime-Boost Vaccination Strategies.. CVI 13: 747-757 [Abstract] [Full Text]  
  • Staib, C., Kisling, S., Erfle, V., Sutter, G. (2005). Inactivation of the viral interleukin 1{beta} receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara. J. Gen. Virol. 86: 1997-2006 [Abstract] [Full Text]  
  • Hutchings, C. L., Gilbert, S. C., Hill, A. V. S., Moore, A. C. (2005). Novel Protein and Poxvirus-Based Vaccine Combinations for Simultaneous Induction of Humoral and Cell-Mediated Immunity. J. Immunol. 175: 599-606 [Abstract] [Full Text]  
  • Redwood, A. J., Messerle, M., Harvey, N. L., Hardy, C. M., Koszinowski, U. H., Lawson, M. A., Shellam, G. R. (2005). Use of a Murine Cytomegalovirus K181-Derived Bacterial Artificial Chromosome as a Vaccine Vector for Immunocontraception. J. Virol. 79: 2998-3008 [Abstract] [Full Text]  
  • Ludwig, H., Mages, J., Staib, C., Lehmann, M. H., Lang, R., Sutter, G. (2005). Role of Viral Factor E3L in Modified Vaccinia Virus Ankara Infection of Human HeLa Cells: Regulation of the Virus Life Cycle and Identification of Differentially Expressed Host Genes. J. Virol. 79: 2584-2596 [Abstract] [Full Text]  
  • Tscharke, D. C., Karupiah, G., Zhou, J., Palmore, T., Irvine, K. R., Haeryfar, S.M. M., Williams, S., Sidney, J., Sette, A., Bennink, J. R., Yewdell, J. W. (2005). Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. JEM 201: 95-104 [Abstract] [Full Text]  
  • Wang, Z., La Rosa, C., Mekhoubad, S., Lacey, S. F., Villacres, M. C., Markel, S., Longmate, J., Ellenhorn, J. D. I., Siliciano, R. F., Buck, C., Britt, W. J., Diamond, D. J. (2004). Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells. Blood 104: 847-856 [Abstract] [Full Text]  
  • Guerra, S., Lopez-Fernandez, L. A., Conde, R., Pascual-Montano, A., Harshman, K., Esteban, M. (2004). Microarray Analysis Reveals Characteristic Changes of Host Cell Gene Expression in Response to Attenuated Modified Vaccinia Virus Ankara Infection of Human HeLa Cells. J. Virol. 78: 5820-5834 [Abstract] [Full Text]  
  • Gherardi, M. M., Perez-Jimenez, E., Najera, J. L., Esteban, M. (2004). Induction of HIV Immunity in the Genital Tract After Intranasal Delivery of a MVA Vector: Enhanced Immunogenicity After DNA Prime-Modified Vaccinia Virus Ankara Boost Immunization Schedule. J. Immunol. 172: 6209-6220 [Abstract] [Full Text]  
  • Wang, Z., La Rosa, C., Maas, R., Ly, H., Brewer, J., Mekhoubad, S., Daftarian, P., Longmate, J., Britt, W. J., Diamond, D. J. (2004). Recombinant Modified Vaccinia Virus Ankara Expressing a Soluble Form of Glycoprotein B Causes Durable Immunity and Neutralizing Antibodies against Multiple Strains of Human Cytomegalovirus. J. Virol. 78: 3965-3976 [Abstract] [Full Text]  
  • Anderson, R. J., Hannan, C. M., Gilbert, S. C., Laidlaw, S. M., Sheu, E. G., Korten, S., Sinden, R., Butcher, G. A., Skinner, M. A., Hill, A. V. S. (2004). Enhanced CD8+ T Cell Immune Responses and Protection Elicited against Plasmodium berghei Malaria by Prime Boost Immunization Regimens Using a Novel Attenuated Fowlpox Virus. J. Immunol. 172: 3094-3100 [Abstract] [Full Text]  
  • Gallego-Gomez, J. C., Risco, C., Rodriguez, D., Cabezas, P., Guerra, S., Carrascosa, J. L., Esteban, M. (2003). Differences in Virus-Induced Cell Morphology and in Virus Maturation between MVA and Other Strains (WR, Ankara, and NYCBH) of Vaccinia Virus in Infected Human Cells. J. Virol. 77: 10606-10622 [Abstract] [Full Text]  
  • Fischer, T., Planz, O., Stitz, L., Rziha, H.-J. (2003). Novel Recombinant Parapoxvirus Vectors Induce Protective Humoral and Cellular Immunity against Lethal Herpesvirus Challenge Infection in Mice. J. Virol. 77: 9312-9323 [Abstract] [Full Text]  
  • Gherardi, M. M., Ramirez, J. C., Esteban, M. (2003). IL-12 and IL-18 act in synergy to clear vaccinia virus infection: involvement of innate and adaptive components of the immune system. J. Gen. Virol. 84: 1961-1972 [Abstract] [Full Text]  
  • Goonetilleke, N. P., McShane, H., Hannan, C. M., Anderson, R. J., Brookes, R. H., Hill, A. V. S. (2003). Enhanced Immunogenicity and Protective Efficacy Against Mycobacterium tuberculosis of Bacille Calmette-Guerin Vaccine Using Mucosal Administration and Boosting with a Recombinant Modified Vaccinia Virus Ankara. J. Immunol. 171: 1602-1609 [Abstract] [Full Text]  
  • Gherardi, M. M., Najera, J. L., Perez-Jimenez, E., Guerra, S., Garcia-Sastre, A., Esteban, M. (2003). Prime-Boost Immunization Schedules Based on Influenza Virus and Vaccinia Virus Vectors Potentiate Cellular Immune Responses against Human Immunodeficiency Virus Env Protein Systemically and in the Genitorectal Draining Lymph Nodes. J. Virol. 77: 7048-7057 [Abstract] [Full Text]  
  • Mulryan, K., Ryan, M. G., Myers, K. A., Shaw, D., Wang, W., Kingsman, S. M., Stern, P. L., Carroll, M. W. (2002). Attenuated Recombinant Vaccinia Virus Expressing Oncofetal Antigen (Tumor-associated Antigen) 5T4 Induces Active Therapy of Established Tumors. Molecular Cancer Therapeutics 1: 1129-1137 [Abstract] [Full Text]  
  • Ober, B. T., Bruhl, P., Schmidt, M., Wieser, V., Gritschenberger, W., Coulibaly, S., Savidis-Dacho, H., Gerencer, M., Falkner, F. G. (2002). Immunogenicity and Safety of Defective Vaccinia Virus Lister: Comparison with Modified Vaccinia Virus Ankara. J. Virol. 76: 7713-7723 [Abstract] [Full Text]  
  • Ramirez, J. C., Tapia, E., Esteban, M. (2002). Administration to mice of a monoclonal antibody that neutralizes the intracellular mature virus form of vaccinia virus limits virus replication efficiently under prophylactic and therapeutic conditions. J. Gen. Virol. 83: 1059-1067 [Abstract] [Full Text]  
  • Brockman, M. A., Knipe, D. M. (2002). Herpes Simplex Virus Vectors Elicit Durable Immune Responses in the Presence of Preexisting Host Immunity. J. Virol. 76: 3678-3687 [Abstract] [Full Text]  
  • Harrington, L. E., Most, R. v. d., Whitton, J. L., Ahmed, R. (2002). Recombinant Vaccinia Virus-Induced T-Cell Immunity: Quantitation of the Response to the Virus Vector and the Foreign Epitope. J. Virol. 76: 3329-3337 [Abstract] [Full Text]  
  • Ramírez, J. C., Gherardi, M. M., Rodríguez, D., Esteban, M. (2000). Attenuated Modified Vaccinia Virus Ankara Can Be Used as an Immunizing Agent under Conditions of Preexisting Immunity to the Vector. J. Virol. 74: 7651-7655 [Abstract] [Full Text]  
  • Gherardi, M. M., Ramírez, J. C., Esteban, M. (2000). Interleukin-12 (IL-12) Enhancement of the Cellular Immune Response against Human Immunodeficiency Virus Type 1 Env Antigen in a DNA Prime/Vaccinia Virus Boost Vaccine Regimen Is Time and Dose Dependent: Suppressive Effects of IL-12 Boost Are Mediated by Nitric Oxide. J. Virol. 74: 6278-6286 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»